Intelligent Nanomaterials for Gene Therapy
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".
Deadline for manuscript submissions: 1 July 2024 | Viewed by 184
Special Issue Editor
Interests: stimuli-responsive nanocarriers; biodegradable polymer spheres; drug delivery; gene delivery; protein delivery
Special Issue Information
Dear Colleagues,
We are pleased to announce a forthcoming Special Issue of Pharmaceutics, entitled “Intelligent Nanomaterials for Gene Therapy”.
Messenger RNAs (mRNAs) are RNA molecules that carry genetic information, serving as a template during protein synthesis. The expression of some specific mRNAs is aberrantly upregulated or downregulated in many types of tumor cells compared to that in normal tissue, which is closely related to various features of tumor progressions, such as proliferation, differentiation migration and invasion of tumor cells. Therefore, designing nanomaterials to deliver anti-tumor mRNAs containing encoded antigen proteins, or inhibiting oncogenic mRNAs such as mRNAs related to c-myc, cyclins, BCL-2 and VEGF would be a promising tumor therapy strategy. Although various targeted nanomaterials have been explored to perform mRNAs delivery and inhibition in tumor cells, the therapeutic efficiency of these genetic therapies is still insufficient for clinic application. It could be attributed to the low bio-stability and possible unexpected pleiotropy of mRNAs, the off-target effects of mRNA inhibitors, as well as the nonspecific uptake of nanomaterials by kidney/liver and their poor retention within tumor. Therefore, it is important to develop a novel nanomaterial to achieve better gene therapy.
We are seeking submissions of original research articles and reviews. Research areas may include (but are not limited to) Materials Science; Chemistry; Biomedical Engineering; Basic and Clinical Medicine.
We look forward to receiving your contributions.
Prof. Dr. Xin Chen
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- physiologically responsive nanomaterials
- mRNAs delivery
- mRNAs inhibition
- multimode gene therapy
- tumor elimination and metastasis inhibition
